Efficacy of apatinib on multiple advanced-stage nongastric cancers

Simple item page
dc.contributor.authorWu, Xueyuanen_US
dc.contributor.authorWang, Haowenen_US
dc.contributor.authorWu, Yueen_US
dc.contributor.authorJin, Jingjingen_US
dc.contributor.authorYu, Zhanen_US
dc.contributor.authorZhu, Guanxiaen_US
dc.contributor.authorZhang, Fengminen_US
dc.contributor.authorZhang, Chaoleien_US
dc.contributor.authorGan, Jianfengen_US
dc.contributor.authorWenfeng, Lien_US
dc.date.accessioned2020-11-18T10:07:23Z
dc.date.available2020-11-18T10:07:23Z
dc.date.issued2019-08
dc.description.abstractBackground: Apatinib has been approved for the treatment of advanced gastric adenocarcinoma and gastric-esophageal junctional adenocarcinoma, but its efficacy is unknown for other advanced solid tumors. Aims and Objectives: We retrospectively reviewed the use of apatinib for multiple advanced-stage non-gastric cancers. Ninety-two patients from 7 hospitals who received additional treatment except apatinib more than once were enrolled. Materials and Methods: The primary end-point was the overall response rate (ORR), and the secondary end-points included progression-free survival (PFS), disease control rate (DCR), overall survival, and adverse reactions. We categorized all the patients into six groups according to their cancer type. Results: In the lung cancer group, the ORR was 9% (95% confidence interval [CI], 3%–23%), DCR was 88% (95% CI, 74%–96%), and median PFS was 3 months (95% CI, 1.9–5.4 months). In the cervical cancer group, the ORR was 25% (95% CI, 3%–65%), DCR reached 100%, and median PFS was 3.5 months (95% CI, 0.6–9.0 months). There were different ORRs between the other cancer groups. In addition, the most common adverse effect of apatinib was palmar–plantar erythrodysesthesia syndrome (37%), followed by proteinuria (14%) and hypertension (13%). Conclusion: These results suggest that apatinib might be effective for not only gastric cancer but also other carcinomas including lung cancer, colorectal cancer, cervical cancer, liver cancer, breast cancer, and nasopharyngeal cancer. Thus, apatinib is a promising targeted drug for multiple types of canceren_US
dc.identifier.affiliationsDepartment of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University; Department of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Clinical Medicine, People's Hospital of Hangzhou Medical College, Zhejiang; Department of Interventional Medicine, Zhejiang Provincial People's Hospital, Hangzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University; Department of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University; Department of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University; Department of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Chemoradiotherapy, The First Affiliated Hospital of Wenzhou Medical University; Department of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.affiliationsDepartment of Clinical Medicine, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Chinaen_US
dc.identifier.citationWu Xueyuan, Wang Haowen, Wu Yue, Jin Jingjing, Yu Zhan, Zhu Guanxia, Zhang Fengmin, Zhang Chaolei, Gan Jianfeng, Wenfeng Li. Efficacy of apatinib on multiple advanced-stage nongastric cancers. Journal of Cancer Research and Therapeutics. 2019 Aug; 15(4): 836-841en_US
dc.identifier.issn0973-1482
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/213440
dc.languageenen_US
dc.publisherWolters Kluwer India Pvt. Ltd.en_US
dc.relation.issuenumber4en_US
dc.relation.volume15en_US
dc.source.urihttps://dx.doi.org//10.4103/jcrt.JCRT_24_19en_US
dc.titleEfficacy of apatinib on multiple advanced-stage nongastric cancersen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijcrt2019v15n4p836.pdf
Size:
896.61 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Cancer Research and Therapeutics